CRO Market Dynamics | Explore ICON's navigation of industry challenges, including bookings volatility and demand uncertainties in the competitive CRO landscape |
Financial Resilience | Delve into ICON's solid financial health, with EPS forecasts of $13.40 (FY1) and $14.06 (FY2), despite recent market pressures |
Strategic Positioning | Learn how ICON leverages proprietary technology and global scale to capture high-quality opportunities in a shifting pharmaceutical landscape |
Valuation Insights | Analysts set price targets ranging from $155 to $263, suggesting potential for value realization as transient headwinds subside |
Metrics to compare | ICLR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICLRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 49.9x | 23.3x | −0.5x | |
PEG Ratio | −0.74 | −1.15 | 0.00 | |
Price/Book | 1.2x | 2.7x | 2.6x | |
Price / LTM Sales | 1.4x | 2.3x | 3.0x | |
Upside (Analyst Target) | 3.7% | 23.8% | 58.7% | |
Fair Value Upside | Unlock | 13.8% | 10.3% | Unlock |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.